Anti-IL-12/IL-23p40 antibodies, such as ustekinumab, are used in methods and compositions for safe and effective treatment of psoriasis, particularly moderate to severe chronic plaque psoriasis, in pediatric patients. The methods and compositions address a clear unmet medical need in this patient population.

Mixed allergen compositions of two or more different allergens are provided. In some instances, the mixed allergen compositions include: a nut allergen; an animal allergen; and at least one of: a non-nut plant allergen; a biotic agent; and a vitamin. Also provided are methods of administering the mixed allergen compositions to a subject. The mixed allergen compositions find use in a variety of applications, including health maintenance, immune balance, gut balance, immune support, health improvement and therapeutic applications.

Provided are methods of treating cancer that comprise administering a polypeptide (e.g. a fusion polypeptide) that comprises a SIRPα D1 domain variant and an Fc domain variant in combination with at least one chemotherapy agent and/or at least one therapeutic antibody. Also provided are related kits.

The present invention relates to an anti-BLyS antibody for use in the treatment of proteinuric kidney disease, for example in the treatment of lupus nephritis. The invention also relates to dosages, duration of treatment and treatment transition for patients moving from intravenous to subcutaneous therapy.

The invention provides compositions and methods for preventing or reducing the severity of malaria.

Provided are dosing regimens of polyomavirus neutralizing antibodies and related methods and pharmaceutical compositions for treating polyomavirus infections.

Methods are provided for preventing the development of a new allergic condition or the worsening of an existing concomitant allergic condition in a subject having an atopic disease such as atopic dermatitis. In one aspect, the methods comprise administering to the subject a course of therapy of an IL-4/IL-13 antagonist, such as an anti-IL-4R antibody or antigen-binding fragment thereof.

The present invention relates to improved treatment of cancer, in particular to a treatment with a composition of CTL peptides for patients after a treatment with an immune checkpoint inhibitor.

Provided are compositions and methods for using the same. In some embodiments, the compositions include an EPELN encapsulating and/or having associated therewith an active agent and a plasma membrane derived from a tumor and/or cancer cell coating the EPELN. In some embodiments, the active agent is a therapeutic agent or an immune response modifier, and in some embodiments the plasma membrane has one or more tumor-associated and/or cancer-associated antigens. Also provided are methods for using the compositions for treating tumors and/or cancers, inducing anti-tumor and/or anti-cancer immune responses, activating antigen-presenting cells, targeting CD11c dendritic cells, and preventing or reducing metastasis.

Disclosed herein is a vaccine comprising a Coronavirus disease 2019 (COVID-19) antigen in a combination with an immunoglobulin from post-exposure treatment. The antigen can be a consensus antigen. The consensus antigen can be a consensus spike antigen. Also disclosed herein is a method of treating a subject in need thereof, by administering the vaccine to the subject.